ClinicalTrials.gg
CompletedNCT06528665Updated Feb 25, 2026

Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects

An observational study in Multiple Sclerosis and Ulcerative Colitis, sponsored by Corium Innovations, Inc.. Completed at 1 site in Malaysia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Corium Innovations, Inc. (formerly part of Corium, Inc.) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn how Ozanimod drug can be administered to the healthy subjects via transdermal delivery system (TDS, patch) to achieve better drug absorption and delivery than via oral capsules (Zeposia). Researchers will compare two administered routes of Ozanimod TDS and oral Zeposia in drug pharmacokinetics, tolerability and safety. Participants will either take one capsule only or wear a patch on his/her arm for 7 days, and blood samples will be collected to measure drug concentrations and local skin reactions will be also observed.

Read the detailed description

This is a single-dose, single-center, open-label, randomized, parallel relative bioavailability study (4 treatments and 1 period) of 3 test products of a Transdermal Delivery System of Ozanimod (Corplex Ozanimod TDS) with the Reference Listed Drug (Zeposia Capsule 0.92 mg), recruiting around 24 healthy (male: female = 1:1) subjects under fasting conditions.

The following goals will be procured through this study:

  1. To determine the pharmacokinetic profiles of Ozanimod and its' major metabolites (CC112273 and CC1084037) from the Corplex Ozanimod TDS (OZ-TDS 1, OZ-TDS 2 and OZ-TDS 3 manufactured by Corium Innovations, Inc.) (Test Product 1, Test Product 2 and Test Product 3) and the comparator (Zeposia Capsule 0.92 mg manufactured by Bristol Myers Squibb) (Reference Product) in healthy subjects;
  2. To compare the relative bioavailability between the Corplex Ozanimod TDS and the oral capsules in healthy subjects;
  3. To compare three formulations of the Corplex Ozanimod TDS in healthy subjects;
  4. To determine the safety and tolerability of the Corplex Ozanimod TDS vs the oral capsules in healthy subjects.
02

Conditions studied

  • Multiple Sclerosis
  • Ulcerative Colitis

Keywords

  • Ozanimod; Transdermal Delivery system; Pharmacokinetics
03

In context

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

This study's enrollment of 24 is below the median of 100 across 971 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Corium Innovations, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

First submitted after Corium Innovations, Inc. left Corium, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Local subjects participate in the Hospital Ampang, Malaysia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject age between 18 to 55 years old.
  2. Subject body weight ≤ 120 kg, with a within 18-30 kg/m2.
  3. Subject is able to complete the clinical study including the follow-up.
  4. Subject is capable of providing written .

Exclusion criteria

Exclusion Criteria:

  1. Breastfeeding female.
  2. Pregnancy test positive female.
  3. At rest systolic blood pressure outside 90-140 mmHg or diastolic blood pressure outside 50-90 mmHg.
  4. At rest sinus bradycardia defined as symptomatic heart rate \< 50 bpm, or asymptomatic heart rate \< 45 bpm; and sinus tachycardia defined as heart rate \> 100 bpm.
  5. abnormalities or Participant with history or presence of second-degree atrioventricular (AV) block Type II or third-degree AV block or sick sinus syndrome unless the patient has a functioning pacemaker.
  6. \> 450 ms for male and \> 460 ms for female.
  7. A history of allergies, or any significant adverse reactions, to any medications, unless the clinician considers that they are not clinically significant.
  8. Clinically significant medical history of eyes, ears, nose, throat, respiratory, cardiovascular, gastrointestinal, genitourinary, neurological, haematopoietic, lymphatic, endocrine, metabolic, dermatological, musculoskeletal, psychological, family history or surgical history.
  9. Family history of sudden cardiac death.
  10. Clinically significant physical examination finding.
  11. Clinically significant laboratory abnormalities.
  12. \< 12.0 g/dL for male and \< 11.0 g/dL for female at screening.
  13. Total \> 1.25 x (unless it is an isolated elevation where the direct bilirubin is ≤ 35% of total), /AST \> 1.5 x upper limit of normal, or CK \> 2 x upper limit of normal.
  14. , or positive.
  15. Urine DOA test positive.
  16. Breath alcohol test positive.
  17. Any use of tobacco product(s) 30 days prior to study recruitment.
  18. A history of drug or substance abuse, including alcohol (≥ 14 units per week) within 6 months before consent taking (1 unit of alcohol equals approximately ½ pint [285 mL] of beer, 1 glass [125 mL] of wine, or 1 shot [25 mL] of spirit).
  19. Unable to refrain from taking any medications (including herbal remedies) within 7 days before dosing, with the exception of medications and other medications deemed acceptable by the Investigator.
  20. Clinically significant illness or injury or hospitalisation for any reason within 28 days before consent-taking.
  21. Unable to refrain or has participation in other clinical study involving a marketed or drug within 28 days or 10 half-lives of the drug before dosing, whichever is longer.
  22. Unable to refrain or has donation of \> 500 mL of plasma within 14 days before dosing; or donation or loss of whole blood (excluding the amount of blood collected during screening) before dosing as follows:

    • 50-300 mL within 28 days,
    • 301-500 mL within 42 days, or
    • \> 500 mL within 84 days.
  23. Any upper arm conditions that will disallow study drug administration or difficulty to swallow the study drug.
  24. Any other medical condition or reason that, in the opinion of the Investigator or Research Physician, makes the subject unsuitable to participate in the clinical study.
  25. Unable to refrain from taking any of the following systemic medications:

    Strong inhibitors of , and all inhibitors of CYP2C8 or BCRP, (i.e., cyclosporine eltrombopag, geftinib) within 7 days or 5 half-lives, whichever is longer, prior to dosing or Strong inducers of CYP3A, and all inducers of CYP2C8 within 14 days or 5 half-lives, whichever is longer, prior to dosing, or Any known MAO inhibitors within 30 days or 5 half-lives, whichever is longer, prior to Day 1.

    Examples of MAO inhibitors include but are not limited to phenelzine, selegiline, isocarboxazid, rasagiline, tranylcypromine, pargyline, procarbazine, and furazolidone.

  26. Female of unable to refrain from having unprotected sexual intercourse with any non-sterile male partner within 14 days before dosing; acceptable methods of contraception include:

    • double barrier (1 by each partner), and at least 1 of these barriers (condom, cervical cap, diaphragm or sponge) must contain spermicide,
    • hormonal (oral, injectable, transdermal, intravaginal or implantable),
    • intrauterine contraceptive system,
    • surgical (vasectomy or tubal ligation), or
    • sexual abstinence.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (actual)
Target follow-up
15 Days
Patient registry
Yes

Groups and cohorts

  • 4 groups subjects will be recruited. Each group will be composed of 6 subjects, sex ratio 1:1

    Group1, 2,3 will be administered with 3 different patches (TDS) once for a week, respectively; Group 4 will be oral administered with one capsule (0.92 mg) only.

    Drug: ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults

Interventions

  • DrugZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults

    ZEPOSIA® * Titration is required for treatment initiation. * The recommended maintenance dosage is 0.92 mg orally once daily. * If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned.

06

What researchers measure

Primary outcomes

  1. Plasma Pharmacokinetic- AUC 0-t (Ozanimod, CC112273, CC1084037)

    area under the concentration-time curve from time-zero to the time of the last quantifiable concentration

    Time frame: 15 days

  2. Plasma Pharmacokinetic- AUC 0-∞ (Ozanimod, CC112273, CC1084037)

    area under the concentration-time curve from time-zero to infinity

    Time frame: 15 days

  3. Plasma Pharmacokinetic- Cmax (Ozanimod, CC112273, CC1084037)

    Peak concentration within the dosing interval

    Time frame: 15 days

  4. Plasma Pharmacokinetic- Tmax (Ozanimod, CC112273, CC1084037)

    Time to peak concentration (Cmax)

    Time frame: 15 days

  5. Plasma Pharmacokinetic- T 1/2 (Ozanimod, CC112273, CC1084037)

    Terminal elimination half-life

    Time frame: 15 days

  6. Plasma Pharmacokinetic- MTR(Ozanimod, CC112273, CC1084037)

    Mean residence time

    Time frame: 15 days

  7. Plasma Pharmacokinetic-Lambda z(λz) (Ozanimod, CC112273, CC1084037)

    Terminal elimination rate constant

    Time frame: 15 days

07

Study locations

1 site
  • Hospital Ampang
    Ampang, Selangor 68000, Malaysia
08

References and documents

Publications

  • Tran JQ, Zhang P, Ghosh A, Liu L, Syto M, Wang X, Palmisano M. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. Adv Ther. 2020 Oct;37(10):4381-4395. doi: 10.1007/s12325-020-01473-0. Epub 2020 Aug 28. PubMed 32857315 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Mar 2025, 1 month.

Of 91 industry-sponsored observational studies under Multiple Sclerosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's 1 month is below that.

Counting every sponsor, half of 426 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Feb 10, 2025
Primary completionActual
Mar 16, 2025
CompletionActual
Apr 16, 2025
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06528665
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Feb 10, 2025
Primary completion
Mar 16, 2025
Completion
Apr 16, 2025
Last update
Feb 25, 2026

Study contacts

Damenthi Nair, MD
principal investigator · Hospital Ampang, 68000 Ampang, Malaysia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion